Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
13 Agosto 2024 - 5:08AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON
D.C. 20549
FORM
12b-25
Commission
File Number 001-41488
NOTIFICATION
OF LATE FILING
(Check
One):
☐
Form 10-K |
☐
Form 11-K |
☐
Form 20-F |
☒
Form 10-Q |
☐
Form N-SAR |
For
Period Ended: June 30, 2024
☐
Transition Report on Form 10-K |
|
☐
Transition Report on Form 10-Q |
☐
Transition Report on Form 20-F |
|
☐
Transition Report on Form N-SAR |
☐
Transition Report on Form 11-K |
|
|
For
the Transition Period Ended:
Read
Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
Part
I-Registrant Information
Full
Name of Registrant |
|
Shuttle
Pharmaceuticals Holdings, Inc. |
|
|
|
Former
Name if Applicable |
|
|
|
|
|
Address
of principal executive office |
|
401
Professional Drive, Suite 260 |
|
|
|
City,
State and Zip Code |
|
Gaithersburg,
MD 20879 |
Part
II-Rules 12b-25 (b) and (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate) ☒
a. |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
b. |
The
subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed
on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on
Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
c. |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
Part
III-Narrative
State
below in reasonable detail the reasons why the form 10-K, 11-K, 20-F, 10-Q or N-SAR, or the transition report or portion thereof could
not be filed within the prescribed time period. (Attach extra sheets of needed.)
The
Registrant is unable to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”)
without unreasonable effort and expense because, as previously reported on the Company’s Current Report on Form 8-K dated July
10, 2024, the Registrant is in the process of restating its financial statements contained in its Annual Report on Form 10-K for the
year ended December 31, 2023 (the “Restatement”), and will be filing an amendment to its Form 10-K (the “10-K/A”)
including the Restatement, and such Restatement will impact the consolidated balance sheet for the year ended December 31, 2023 contained
in the Form 10-Q. The Company is aiming to file the Form 10-K/A in advance of filing the Form 10-Q and intends to file the Form 10-Q
as soon as possible thereafter, with the aim of completing all required filings within the five-day extension period provided under Rule
12b-25 of the Securities Exchange Act of 1934, as amended.
Part
IV-Other Information
1. |
Name
and telephone number of person to contact in regard to this notification |
Timothy
J. Lorber |
|
(240) |
|
430-4212 |
(Name) |
|
(Area
Code) |
|
(Telephone
No.) |
2. |
Have
all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s). |
Yes☒
No☐
3. |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
Yes
☐ No☒
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Shuttle
Pharmaceuticals Holdings, Inc.
(Name
of Registrant as specified in charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
August 13, 2024 |
By:
|
/s/
Timothy J. Lorber |
|
|
Timothy
J. Lorber, Chief Financial Officer |
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024